Background:
A disproportional increase in in situ or thin melanomas may point at underlying causes such as increased melanoma awareness, as well as 'overdiagnosis' of melanoma in diagnostically equivocal small lesions.
Objectives:
The purposes of this study were to estimate trends in melanoma incidence by sex, Breslow thickness (thin melanomas subdivided into four subgroups: <0.25 mm, 0.25-0.49 mm, 0.50-0.74 mm, and 0.75-1.0 mm), age and location, and to compare these with trends in subgroups of thicker melanomas.
Methods:
Data on all histologically confirmed in situ and invasive melanomas diagnosed between 1994 and 2010 were retrieved from the Netherlands Cancer Registry. Trends in European standardised rates (ESRs) were assessed using joinpoint analysis, and expressed as estimated annual percentage change (EAPC).
Results:
Between 1994 and 2010, 34,156 persons were diagnosed with an in situ or thin melanoma. The ESR of in situ melanomas doubled for males and females with a recent steeper rise in incidence (EAPC 12% (95% confidence interval [CI]: 8.1-16) and 13% (95% CI: 5.9-20), respectively). ESR for thin melanomas amongst males approximately doubled with a steep, but non-significant acceleration compared to other thickness categories since 2006 for <0.25 mm melanomas (EAPC 26% (95% CI: 2.1-35)). For female patients with thin melanomas the ESRs increased almost two-fold, except for <0.25 mm melanomas.
Conclusions:
The incidence rates of in situ, thin and thick melanomas increased similarly between 1994 and 2010. Recently steep increases were found for in situ melanomas and thin melanomas in men. Explanations are 'overdiagnosis' in conjunction with increased ultraviolet exposure (natural and artificial) and therefore a 'true' increase, increased awareness, early detection, diagnostic drift and changed market forces in the Dutch health care system.
Citing Articles
The risk of subsequent invasive melanoma after a primary in situ or invasive melanoma in a high incidence country (New Zealand).
Win Myint T, Selak V, Elwood M
Skin Health Dis. 2023; 3(2):e116.
PMID: 37013115
PMC: 10066759.
DOI: 10.1002/ski2.116.
Patient presentation, skin biopsy utilization and cutaneous malignant melanoma incidence and mortality in northern Italy: Trends and correlations.
Bucchi L, Mancini S, Zamagni F, Crocetti E, Dal Maso L, Ferretti S
J Eur Acad Dermatol Venereol. 2022; 37(2):293-302.
PMID: 36181283
PMC: 10092783.
DOI: 10.1111/jdv.18635.
Clinical findings are not helpful in detecting lentigo maligna melanoma in patients with biopsy-proven lentigo maligna.
Zoutendijk J, Koljenovic S, Wakkee M, Mooyaart A, Nijsten T, van den Bos R
J Eur Acad Dermatol Venereol. 2022; 36(12):2325-2330.
PMID: 35730990
PMC: 9796129.
DOI: 10.1111/jdv.18346.
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
Garbe C, Keim U, Amaral T, Berking C, Eigentler T, Flatz L
J Clin Oncol. 2022; 40(32):3741-3749.
PMID: 35709414
PMC: 9649277.
DOI: 10.1200/JCO.22.00202.
The effect of screening on melanoma incidence and biopsy rates.
Whiteman D, Olsen C, Macgregor S, Law M, Thompson B, Dusingize J
Br J Dermatol. 2022; 187(4):515-522.
PMID: 35531668
PMC: 9796145.
DOI: 10.1111/bjd.21649.
Hypothesised cutaneous sites of origin of stage III melanomas with unknown primary: A multicentre study.
Clayton B, Muneeb F, Hughes M, Grant M, Khosrotehrani K, Smithers B
Int J Cancer. 2022; 151(3):396-401.
PMID: 35403698
PMC: 9325056.
DOI: 10.1002/ijc.34020.
Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040.
Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F
JAMA Dermatol. 2022; 158(5):495-503.
PMID: 35353115
PMC: 8968696.
DOI: 10.1001/jamadermatol.2022.0160.
The relative contribution of the decreasing trend in tumour thickness to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population-based investigation.
Zamagni F, Bucchi L, Mancini S, Crocetti E, Dal Maso L, Ferretti S
Br J Dermatol. 2022; 187(1):52-63.
PMID: 35253204
PMC: 9542017.
DOI: 10.1111/bjd.21051.
Dual Encapsulated Dacarbazine and Zinc Phthalocyanine Polymeric Nanoparticle for Photodynamic Therapy of Melanoma.
do Reis S, Helal-Neto E, da Silva de Barros A, Pinto S, Portilho F, de Oliveira Siqueira L
Pharm Res. 2021; 38(2):335-346.
PMID: 33604784
DOI: 10.1007/s11095-021-02999-w.
Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities.
Forsea A
Dermatol Pract Concept. 2020; 10(3):e2020033.
PMID: 32642304
PMC: 7319793.
DOI: 10.5826/dpc.1003a33.
A 10-year retrospective study of melanoma stage at diagnosis in the academic emergency hospital of Sibiu county.
Rotaru M, Jitian C, Iancu G
Oncol Lett. 2019; 17(5):4145-4148.
PMID: 30944608
PMC: 6444339.
DOI: 10.3892/ol.2019.10098.
Physical activity, cardiorespiratory fitness and risk of cutaneous malignant melanoma: Systematic review and meta-analysis.
Behrens G, Niedermaier T, Berneburg M, Schmid D, Leitzmann M
PLoS One. 2018; 13(10):e0206087.
PMID: 30379884
PMC: 6209223.
DOI: 10.1371/journal.pone.0206087.
The mapping of cancer incidence and mortality trends in the UK from 1980-2013 reveals a potential for overdiagnosis.
Oke J, OSullivan J, Perera R, Nicholson B
Sci Rep. 2018; 8(1):14663.
PMID: 30279510
PMC: 6168593.
DOI: 10.1038/s41598-018-32844-x.
Mitotic rate is associated with positive lymph nodes in patients with thin melanomas.
Wheless L, Isom C, Hooks M, Kauffmann R
J Am Acad Dermatol. 2017; 78(5):935-941.
PMID: 29198779
PMC: 6519988.
DOI: 10.1016/j.jaad.2017.11.041.
Environmental effects of ozone depletion and its interactions with climate change: Progress report, 2016.
Photochem Photobiol Sci. 2017; 16(2):107-145.
PMID: 28124708
PMC: 6400464.
DOI: 10.1039/c7pp90001e.